Australia's most trusted
source of pharma news
Friday, 15 November 2024
Posted 12 November 2024 PM
Former Novartis executive, Rebecca McQualter, has been promoted to CEO of Chimeric Therapeutics after just seven months with the ASX-listed clinical stage cancer cell therapy company.
The appointment, effective immediately, was announced during Chimeric's Annual General Meeting held this morning.
Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.